PCV salvage chemotherapy for recurrent primary CNS lymphoma
- 25 April 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 54 (8) , 1707-1708
- https://doi.org/10.1212/wnl.54.8.1707
Abstract
Radiochemotherapy according to DeAngelis et al.1 and, since 1998, HD-MTX (8 g/m2 body surface area)3 were primary treatments for patients with PCNSL at our institution. All patients presenting with recurrent or progressive PCNSL between 1995 and 1998 were intended to be treated with PCV chemotherapy (procarbazine 60 mg/m2, days 8 through 21; lomustine (CCNU) 110 mg/m2, day 1; vincristine 2 mg, days 8 and 29) …Keywords
This publication has 5 references indexed in Scilit:
- Intravenous Methotrexate as Initial Treatment for Primary Central Nervous System Lymphoma: Response to Therapy and Quality of Life of PatientsJournal of Neuro-Oncology, 1999
- Long-term survival in primary CNS lymphoma.Journal of Clinical Oncology, 1998
- High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.Journal of Clinical Oncology, 1998
- Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent gliomaJournal of Neuro-Oncology, 1998
- Combined modality therapy for primary CNS lymphoma.Journal of Clinical Oncology, 1992